|
| Status |
Public on Dec 31, 2021 |
| Title |
GCN2 kinase Activation by ATP-competitive Kinase Inhibitors |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
Other
|
| Summary |
Purpose: Use next generation sequencing to determine which CRISPR knockouts confer resistance to EGFR inhibitors and to determine which cellular pathways get upregulated in response to neratinib.
|
| |
|
| Overall design |
Glioblastoma cell lines were transduced with the TKOv3 CRISPR KO library and treated with vehicle or neratinib for 14 or 21 days. Transcriptomic data was obtained by treating parental or GCN2-KO SF268 cells with neratinib for 0, 6, or 72 hours.
|
| |
|
| Contributor(s) |
Tang CP, Elemento O, Mellinghoff I |
| Citation(s) |
34949839 |
| |
| Submission date |
Nov 16, 2021 |
| Last update date |
Apr 03, 2022 |
| Contact name |
Colin Tang |
| E-mail(s) |
[email protected]
|
| Organization name |
Weill Cornell Medicine
|
| Street address |
1300 York Ave.
|
| City |
New York |
| State/province |
NY |
| ZIP/Postal code |
10065 |
| Country |
USA |
| |
|
| Platforms (3) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
| GPL15520 |
Illumina MiSeq (Homo sapiens) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (29)
|
|
| Relations |
| BioProject |
PRJNA780901 |
| SRA |
SRP346390 |
Less...
More...